Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.
about
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyMitoxantrone for multiple sclerosisNatalizumab for relapsing remitting multiple sclerosisMitoxantrone for multiple sclerosisNatalizumab: A new treatment for relapsing remitting multiple sclerosisMultiple sclerosisDevelopment of oral immunomodulatory agents in the management of multiple sclerosisSwitching multiple sclerosis patients with breakthrough disease to second-line therapy.Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) studyMitoxantrone: a review of its use in multiple sclerosis.A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.Mitoxantrone (Novantrone) in multiple sclerosis: new insights.The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding.Immunosuppressive agents in multiple sclerosis.Current and future therapies for multiple sclerosis.Quality of life in multiple sclerosis: effects of current treatment options.Adherence to recommended dosing and monitoring for mitoxantrone in patients with multiple sclerosis: a healthcare claims database study supplemented with medical records--the RETRO study.Current and future disease-modifying therapies in multiple sclerosis.A critical appraisal of treatment decisions in multiple sclerosis--old versus new.Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC.Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?Protective Effects of Chrysin Against Drugs and Toxic Agents.Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.A nurse-led, patient-centred mitoxantrone service in neurology.Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients.Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
P2860
Q22241650-C5FD8527-4AB4-4E0E-889F-331C97B174D7Q24202866-40ADEA1B-940B-4C09-9C4C-AE0ED758EBDFQ24235861-D5B71D7A-D2FF-4D12-8571-0D1ECFBE9091Q24245404-36031B6D-BE39-4EA2-9FD0-65724867C92BQ24683014-1A2CC51E-4C30-45AF-BFA5-A989A7F9102AQ26995437-EDCB3788-6888-438A-A8D3-E2F9307CF233Q28388704-C038B030-54CB-4925-89F6-318937A96C0AQ33815455-CFB4651C-FD92-4A4B-B005-B900ED64491DQ33899881-FDE4B786-889E-415C-885C-8139A7A8155BQ34257903-CFFA738F-DF9E-4571-9211-DC45CC1E5E49Q34535269-91351F6F-B888-4CA4-9BFB-56C80D49E736Q34810005-FB1B2E3A-5B3A-4F93-9E2B-BF0DD8C3D43AQ35747877-204017F2-A65F-4672-BB97-1FE9A5DB77B2Q35753383-D5A1F083-F32E-4474-8564-A23FB189ABECQ35818165-7C585A2D-0017-4F29-AB41-6E13734CA739Q36107235-8EB1AD19-E297-46D1-8241-B4075323402CQ36407273-BCB009F5-CE46-4B33-A4AE-3882DAE5572DQ36419566-33676850-ED66-4039-BBA8-A7908E860593Q36688987-C485224C-A3DB-40E2-AA08-53EB76343FC8Q36963189-880253E8-494F-422E-999A-6B45F7BB2966Q37287769-CF9B87F2-FEF6-4946-AA65-08A03D33DBEEQ37710122-2943922B-8AF4-40D7-97D8-9A20C957D18CQ37718137-0F899D2B-7674-4907-80EC-F606565EF689Q37747735-A91FD364-0E67-459A-8149-FF9BA0BF87FDQ37862062-EEDB7B89-5935-47F9-84FB-8182D7F0C3DFQ38164425-BBD269A4-E654-45CE-A3FE-00819151B26CQ38228300-A10952BB-31DD-4641-9418-CC83D8880150Q38685201-1051BDA1-A4B9-451C-BA9A-290CF649AFBBQ42920232-6C8E5F83-4E06-4C3C-A957-C64E9C39C866Q45153766-099906BB-269A-4431-8D29-0587FAECFB22Q45354300-A217FDE3-6C7E-43D6-A69F-54869B233458Q46104696-5632D287-3C0B-4691-8971-8E05548BCA8FQ52855510-AE00A9D3-F750-4343-810C-985F8852F722Q56986554-DD01D1F9-88A0-4755-B93E-29BB7CC29FFB
P2860
Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cardiac adverse effects associ ...... ) therapy in patients with MS.
@ast
Cardiac adverse effects associ ...... ) therapy in patients with MS.
@en
Cardiac adverse effects associated with mitoxantrone
@nl
type
label
Cardiac adverse effects associ ...... ) therapy in patients with MS.
@ast
Cardiac adverse effects associ ...... ) therapy in patients with MS.
@en
Cardiac adverse effects associated with mitoxantrone
@nl
prefLabel
Cardiac adverse effects associ ...... ) therapy in patients with MS.
@ast
Cardiac adverse effects associ ...... ) therapy in patients with MS.
@en
Cardiac adverse effects associated with mitoxantrone
@nl
P2093
P356
P1433
P1476
Cardiac adverse effects associ ...... ) therapy in patients with MS.
@en
P2093
Eisenman S
Gonsette RE
Goodkin DE
P304
P356
10.1212/WNL.59.6.909
P407
P577
2002-09-01T00:00:00Z